US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Braveheart Bio

27.50

-0.0800-0.29%

Post-market: 27.500.00000.00%19:57 EDT

Volume:101.99K

Turnover:2.79M

Market Cap:1.94B

PE:-24.21

High:28.00

Open:27.64

Low:26.17

Close:27.58

52wk High:32.00

52wk Low:24.61

Shares:70.65M

Float Shares:18.75M

Volume Ratio:0.42

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.1360

EPS(LYR):-3.9270

ROE:--

ROA:--

PB:-24.79

PE(LYR):-7.00

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Braveheart Bio

Exchange:

NASDAQ

Establishment Date:

2024

Employees:

30

Office Location:

One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States

Website:

http://www.braveheart.bio

Zip Code:

94129

Phone:

Fax:

- -

Introduction:

Braveheart Bio, Inc. was incorporated under Delaware law on May 13, 2024. The company is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor licensed globally (excluding Greater China) from Jiangsu Hengrui Pharmaceuticals Co., Ltd., and has been evaluated in clinical trials conducted by Hengrui primarily in China and Australia.

Directors

Name

Position

Christopher Viehbacher

Chairman of the Board and Director

Travis Murdoch

Chief Executive Officer, President and Director

David C. Lubner

Director

David Malek

Director

Erez Chimovits

Director

Jason Coloma

Director

Jasper Bos

Director

Tim Lohoff

Director

Vineeta Agarwala

Director

Shareholders

Name

Position

Travis Murdoch

Chief Executive Officer, President and Director

J. Paul Rickey

Chief Financial Officer

Emil deGoma

Chief Medical Officer

Marc Evanchik

Chief Scientific Officer

Michele Anderson

Chief Development Officer

Tyler Chavez

Chief Business Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BRVE/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":27.5,"timestamp":1787601600000,"preClose":27.58,"halted":0,"volume":101993,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.5,"latestTime":"19:57 EDT","volume":49,"amount":1347,"timestamp":1787615879670,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0029006526468454787,"floatShares":18750000,"shares":70652838,"eps":-1.136,"marketStatus":"Closed","change":-0.08,"latestTime":"08-24 16:00:00 EDT","open":27.64,"high":27.995,"low":26.1737,"amount":2793346.4445970003,"amplitude":0.066037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.136,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":27.58,"preHourTrading":{"tag":"盘前","latestPrice":28.46,"preClose":27.58,"latestTime":"05:42 EDT","volume":106,"amount":2979.6998559999997,"timestamp":1787564567151,"change":0.88,"changeRate":0.031907,"amplitude":0.071972},"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.5,"latestTime":"19:57 EDT","volume":49,"amount":1347,"timestamp":1787615879670,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.416733},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":18750000,"roa":"--","roe":"--","lyrEps":-3.927011,"volumeRatio":0.416733,"shares":70652838,"dividePrice":0,"high":27.995,"amplitude":0.066037,"preClose":27.58,"low":26.1737,"week52Low":24.61,"pbRate":"-24.79","week52High":32,"institutionHeld":0,"latestPrice":27.5,"eps":-1.136,"divideRate":0,"volume":101993,"delay":0,"ttmEps":-1.136,"open":27.64,"prevYearClose":18,"prevWeekClose":27.58,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":27.66,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-08-21","current":-24.207746,"percent":0.416667,"low":-23.993466,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"high":-12.297967,"avg":-20.536215,"sd":3.354826,"marketCap":1759511923},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923}],"updateTime":1787616680511},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1959705903,"yearFounded":2024,"employeeNum":30,"address":"One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States","zipCode":"94129","officePhone":"415 707 6312","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.braveheart.bio","stockEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":0.5322},{"period":"ytd","weight":0.5322}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Braveheart Bio, Inc. was incorporated under Delaware law on May 13, 2024. The company is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor licensed globally (excluding Greater China) from Jiangsu Hengrui Pharmaceuticals Co., Ltd., and has been evaluated in clinical trials conducted by Hengrui primarily in China and Australia.","exchange":"NASDAQ","name":"Braveheart Bio","nameEN":"Braveheart Bio"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":{"directors":[{"name":"Christopher Viehbacher","position":"Chairman of the Board and Director"},{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"David C. Lubner","position":"Director"},{"name":"David Malek","position":"Director"},{"name":"Erez Chimovits","position":"Director"},{"name":"Jason Coloma","position":"Director"},{"name":"Jasper Bos","position":"Director"},{"name":"Tim Lohoff","position":"Director"},{"name":"Vineeta Agarwala","position":"Director"}],"executives":[{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"J. Paul Rickey","position":"Chief Financial Officer"},{"name":"Emil deGoma","position":"Chief Medical Officer"},{"name":"Marc Evanchik","position":"Chief Scientific Officer"},{"name":"Michele Anderson","position":"Chief Development Officer"},{"name":"Tyler Chavez","position":"Chief Business Officer"}]}}}